Cystic fibrosis: Meveol effective against Burkholderia dolosa

April 11, 2011

The new generation of antimicrobial confirmed its potential with the evidence of effectiveness on this resistant bacterium kindly provided by Harvard Children's Hospital for which no therapeutic solution is available to date.

Lyon April 4th, 2011. Alaxia, a Lyons biotech that is developing the candidate drug Meveol hired an independent certified laboratory to confirm in vitro efficacy recorded by its microbiologists. The effect of Meveol has been studied on several strains of Burkholderia dolosa. Meveol bactericidal efficacy - over 99.9% - is observed in a few hours.

These results were obtained as part of a research partnership with Harvard Children's Hospital, Boston (USA), as Burkholderia dolosa affects their cystic fibrosis patients. This highly pathogen strain for CF patients is resistant to all known antibiotics.

Directly exiting Alaxia peroxidase platform, Meveol has already shown its effectiveness on many bacteria (+Gram, -Gram): eg mucoïd Pseudomonas aeruginosa, MRSA, Mycobacterium abscessus, Burkholderia cepacia. ... even on biofilm form.

"The effectiveness demonstrated over a superbacteria further confirms that the drug candidate Meveol opens a new therapeutic approach, particularly towards antibiotic-resistant bacteria, and this well beyond cystic fibrosis” said Philippe Bordeau, Alaxia CEO.

Alaxia focuses its efforts primarily on the inhaled form of the drug for cystic fibrosis application, and plans to finalize a new financial round in 2011 to accelerate development and to develop its own pipeline (URTI, LRTI, COPD, ...)

Part of these results will be presented during the conference "Progress in Antimicrobial Therapies" at the congress of the European Society of Cystic Fibrosis (ECFS), in Hamburg in June.


The OSCN / Lactoferrin, developed under the name of Meveol, was designated orphan drug for cystic fibrosis in Europe and the United States.


- Is effective across a wide spectrum of bacteria, including multiresistant ones or gathered in biofilm.

- Presents no risk of antibiotic resistance

- Uses compounds present in the healthy lung, at physiological doses.

- Has a direct action by inhalation


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.